logo
What is ‘sleep divorce' — and why is this concerning trend becoming more popular?

What is ‘sleep divorce' — and why is this concerning trend becoming more popular?

New York Post31-05-2025
There's been a dramatic spike in the number of couples agreeing to part ways in the bedroom as Australia's growing sleep crisis worsens.
New data shows that nearly one in three Australians are struggling to fall or stay asleep three or more times a week, sparking a rise in the number of couples who have embarked on a 'sleep divorce', opting to get their nightly rest in separate beds or rooms – despite ongoing stigma surrounding the decision.
Advertisement
The research, conducted by leading sleep device manufacturer ResMed for its 2025 Global Sleep Survey, has revealed sleep deprivation is so bad that almost 1 in 5 (18 per cent) of Australians have called in sick.
6 Nearly one in three Australians are struggling to fall or stay asleep three or more times a week, leading to couples getting their nightly rest in separate beds or rooms.
Pixel-Shot – stock.adobe.com
But shockingly, 41 percent of Aussies are choosing to 'just live with' the consequences of a bad night's kip, almost double the global average.
'This year's Resmed Global Sleep Survey found that the top factors causing Australians to have a poor night's sleep are stress (47 percent), followed by anxiety (42 percent) and financial pressures (26 percent),' Dr. Alison Wimms, Director of Medical Affairs for the company, told news.com.au.
Advertisement
'Screen time, and inconsistent routines also widely affect sleep in Australia.'
6 41 percent of Aussies are choosing to 'just live with' the consequences of a bad night's kip, almost double the global average.
terovesalainen – stock.adobe.com
Some of those not willing to put up with a poor night's sleep have decided to embark on a 'sleep divorce', with 61 percent of Aussies who have ditched their partner at bedtime reporting a better sleep quality.
'26 per cent said it improved their relationship, and almost 16 per cent noted a positive impact on their sex life,' Dr. Wimms added.
Advertisement
'Sleeping separately can also improve sleep quality by reducing disturbances from different schedules, snoring, or movement during sleep.'
However sleeping separately does not work for everybody, with 38 percent of the 1 in 5 Australians who opted for a sleep separation – often due to snoring and restlessness – stating they felt their quality of sleep got worse or remained the same.
Alarmingly, almost 1 in 5 of those who have split up at night said they felt their relationship and sex life took a turn for the worse after sleeping apart.
Advertisement
Sydney couple's therapist Shahn Baker Sorekli however warns that while a sleep separation 'can be helpful in some circumstances', he doesn't always recommend it.
6 According to a survey, 38 percent of the 1 in 5 Australians who opted for a sleep separation – often due to snoring and restlessness – said they felt their quality of sleep worsen or remained the same.
motortion – stock.adobe.com
'The main reason is coming together at the end of the night allows for a bit of a nice routine for the relationship where you can have a moment of connection and intimacy,' news.com.au's podcast, From the Newsroom.
'I'm not talking about, you know, long deepened meaningfuls in bed. It might just be a little snuggle, might just be reading next to each other, but kind of coming together at the end of the night.
'Being a couple, just unwinding is just a nice point of connection. And if you can maintain a good sleep routine together, it can just be really healthy for the relationship. So you close off the world, you in your room together, snuggling away.'
6 'If you can maintain a good sleep routine together, it can just be really healthy for the relationship,' couple's therapist Shahn Baker Sorekli says.
Allistair F/peopleimages.com – stock.adobe.com
The clinical psychologist, who authored relationship book The 8 Love Links, said that for those who find sleeping apart 'improves sleep quality it's absolutely a good idea'.
'For example, if one person is a really restless sleeper or somebody has a problem with snoring or perhaps somebody does shift work… and it going to add to the relationship tension, that's when it's a good idea,' he shared.
Advertisement
'You've just got to be careful not to get into any kind of the pitfalls around it.
6 If sleeping together is 'going to add to the relationship tension, that's when it's a good idea,' Sorekli said about when it is appropriate for separate sleeping arrangements.
WavebreakMediaMicro – stock.adobe.com
Dr. Wimms noted that it is often women who report poorer sleep quality and higher rates of mood disruptions than men, explaining the gap was noticeable.
'38 per cent of Australian women struggle to fall asleep at least 3 nights a week, compared to 26 per cent of men,' she explained.
Advertisement
'This is consistent with global numbers where we see women consistently report more sleep challenges. This may be due to hormonal changes through the month, caregiving responsibilities, or higher stress loads.
6 'We see women consistently report more sleep challenges. This may be due to hormonal changes through the month, caregiving responsibilities, or higher stress loads,' Dr. Wimms said.
Nattakorn – stock.adobe.com
'While 4 in 10 Australian women say that their sleep is disrupted by their partner at least a few times a week, most often because of snoring or loud breathing, compared to 28 per cent of men.'
The report concluded that sleep has become the 'silent casualty of our busy modern lifestyles', noting the 'lines between work and home more blurred than ever'.
Advertisement
Pressures such as the rising cost of living in Australia are also building, resulting in poor sleep across the nation.
But it's not all bad news, with ResMed stating that Australians have become more curious about how they sleep, with 33 percent monitoring their sleep, up from 18 percent last year.
'This increased curiosity, however, has revealed a gap in action with a staggering 41 per cent of Aussies saying they would just live with poor sleep,' Dr. Wimms said.
Advertisement
'This is higher than the 22 per cent globally who indicated that they would do the same. This gap makes it vital for us to drive awareness of the importance of not just knowing, but taking action to improve your sleep health.
'This could be as simple as raising your sleep in a conversation with your healthcare provider or taking an online sleep assessment to learn more about what may be causing your poor sleep.'
Those who have spoken out in the past about the benefits of sleeping separately to their partner include Michael and Lisa Wipfli, Sunrise host Edwina Bartholomew and her husband Neil Varcoe as well as popular porn star Annie Knight who recently announced she sleeps in a separate bed to her new fiance Henry Brayshaw.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb

Yahoo

time11 hours ago

  • Yahoo

Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb

Resmed Inc.'s RMD adjusted earnings per share (EPS) in the fourth quarter of fiscal 2025 were $2.55, up 22.6% year over year. The metric beat the Zacks Consensus Estimate by 3.66%. The adjustments include certain non-recurring expenses/benefits like the amortization of acquired intangibles, along with the income tax effect on those adjustments. GAAP EPS in the reported quarter was $2.58, up 30.3% from the year-ago level. For the full year, adjusted EPS of $9.55 topped the Zacks Consensus Estimate by 0.5%. The metric increased 23.7% from the fiscal 2024 adjusted figure. RMD's Revenue Details On a reported basis, revenues increased 10.2% year over year (up 9% at the constant exchange rate or CER) to $1.35 billion. The figure beat the Zacks Consensus Estimate by 1.87%. Full-year revenues were $5.15 billion, a 9.8% improvement on a reported basis from fiscal 2024 (up 10% at CER). The metric surpassed the Zacks Consensus Estimate by 0.6%. Following the announcement, shares of RMD rose 2.6% in the after-market trading yesterday. ResMed's Q4 Sales: A Closer View ResMed operated through two reporting units — Sleep and Breathing Health (formerly Sleep and Respiratory Care) and Residential Care Software (formerly Software as a Service). Sleep and Breathing Health Total revenues improved 10.2% (up 9% at CER) from the prior-year period's level to $1.18 billion. The figure topped our model's projection of $1.15 billion. Within this business, net revenues from Devices were $693.9 million, up 9.3% (8% at CER). This includes an increase of 7% in the United States, Canada and Latin America and an increase of 14% in combined Europe, Asia and other markets. Our model forecasted Devices revenue to be $683.6 million. ResMed Inc. Price, Consensus and EPS Surprise ResMed Inc. price-consensus-eps-surprise-chart | ResMed Inc. Quote Net revenues from masks and other were $487.1 million, up 11.7% (11% at CER). This encompasses an increase of 12% in the United States, Canada and Latin America and an increase of 11% in combined Europe, Asia and other markets. Our model projected masks and other revenues to be $463.1 million. Residential Care Software Revenues in this segment grew 9.9% year over year (up 9% at CER) to $167 million, which was consistent with our model's projection. Resmed's Q4 Margin Performance In the fiscal fourth quarter, the company's adjusted cost of sales (excluding amortization of acquired intangible, masks with magnet field safety notification expenses and Astral field safety notification expenses) totaled $520.1 million, up 4.1% year over year. Despite that, the adjusted gross profit rose 14.4% to $827.9 million. The adjusted gross margin for the fiscal fourth quarter was 61.4%, reflecting an expansion of 227 basis points (bps). Selling, general and administration expenses rose 9.5% year over year to $265.1 million. Research and development expenses increased 6.9% to $86.4 million. The adjusted operating income was $476.4 million in the quarter, up 19% from the year-ago quarter's level. The adjusted operating margin expanded 260 bps year over year to 35.3%. RMD's Financial Updates Resmed exited the fourth quarter of fiscal 2025 with cash and cash equivalents of $1.21 billion, significantly up from $238.4 million at the end of fiscal 2024. Total debt (short and long-term) amounted to $668.3 million compared with $707.2 million at the end of fiscal 2024. The cumulative net cash provided by operating activities at the end of the fiscal fourth quarter was $1.75 billion compared with $1.40 billion in the year-ago period. Additionally, the company paid out $78 million in dividends in the fiscal fourth quarter and also repurchased 419,000 shares for consideration of $100 million as part of its ongoing capital management. Our Take on RMD Stock Resmed delivered an earnings and revenue beat in the fourth quarter of fiscal 2025. The performance reflected robust global demand for its sleep and breathing health devices, as well as an expanding digital health ecosystem. Mask and other sales in the United States, Canada and Latin America reflected continued growth in ReSupply, new patient setups and incremental revenues from 2 months of owning VirtuOx. The addition of VirtuOx's at-home diagnostic services bolsters Resmed's ability to support patients earlier in their journey and help healthcare providers and homecare companies deliver more streamlined, connected care. Meanwhile, growth in Residential care software revenues was driven by robust performances from the MEDIFOX DAN and HME verticals. Gross margin improvement in the quarter was led by procurement, manufacturing and logistics efficiencies as well as favorable foreign currency movements. Resmed made meaningful progress on its gross margin expansion objectives and continues to advance its gross margin initiative pipeline. RMD's Zacks Rank and Key Picks Resmed currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Medpace Holdings MEDP, GeneDx Holdings WGS and Boston Scientific BSX. Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today's Zacks #1 Rank stocks here. MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite's 10.1% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 13.87%. GeneDx Holdings, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter 2025 adjusted EPS of 50 cents, exceeding the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%. WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry's 18.6% growth. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 231.40%. Boston Scientific, currently carrying a Zacks Rank #2, reported a second-quarter 2025 adjusted EPS of 75 cents, which topped the Zacks Consensus Estimate by 4.2%. BSX has a historical five-year earnings growth rate of 13.3% compared with the industry's 2.7% growth. The company's earnings beat estimates in each of the trailing four quarters, with the average surprise being 8.11%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report ResMed Inc. (RMD) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report GeneDx Holdings Corp. (WGS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

ResMed (NYSE:RMD) Surprises With Q2 Sales
ResMed (NYSE:RMD) Surprises With Q2 Sales

Yahoo

timea day ago

  • Yahoo

ResMed (NYSE:RMD) Surprises With Q2 Sales

Medical device company ResMed (NYSE:RMD) beat Wall Street's revenue expectations in Q2 CY2025, with sales up 10.2% year on year to $1.35 billion. Its non-GAAP profit of $2.55 per share was 3% above analysts' consensus estimates. Is now the time to buy ResMed? Find out in our full research report. ResMed (RMD) Q2 CY2025 Highlights: Revenue: $1.35 billion vs analyst estimates of $1.33 billion (10.2% year-on-year growth, 1.3% beat) Adjusted EPS: $2.55 vs analyst estimates of $2.48 (3% beat) Adjusted EBITDA: $542.9 million vs analyst estimates of $494.7 million (40.3% margin, 9.8% beat) Operating Margin: 33.7%, up from 31.2% in the same quarter last year Free Cash Flow Margin: 37.7%, up from 33.9% in the same quarter last year Constant Currency Revenue rose 9% year on year (10% in the same quarter last year) Market Capitalization: $40.61 billion 'Our strong finish to fiscal year 2025 reflects ongoing momentum across our business, driven by robust global demand for our market-leading sleep and breathing health devices, as well as our expanding digital health ecosystem,' said Resmed's Chairman and CEO, Mick Farrell. Company Overview Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE:RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, ResMed's sales grew at a decent 11.7% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. ResMed's annualized revenue growth of 10.4% over the last two years is below its five-year trend, but we still think the results were respectable. ResMed also reports sales performance excluding currency movements, which are outside the company's control and not indicative of demand. Over the last two years, its constant currency sales averaged 10.3% year-on-year growth. Because this number aligns with its normal revenue growth, we can see that ResMed has properly hedged its foreign currency exposure. This quarter, ResMed reported year-on-year revenue growth of 10.2%, and its $1.35 billion of revenue exceeded Wall Street's estimates by 1.3%. Looking ahead, sell-side analysts expect revenue to grow 8.1% over the next 12 months, a slight deceleration versus the last two years. Despite the slowdown, this projection is noteworthy and suggests the market is forecasting success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin ResMed has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 29%. Analyzing the trend in its profitability, ResMed's operating margin rose by 4.5 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its recent improvements as the company's margin has increased by 5.9 percentage points on a two-year basis. These data points are very encouraging and shows momentum is on its side. This quarter, ResMed generated an operating margin profit margin of 33.7%, up 2.6 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. ResMed's EPS grew at a spectacular 14.9% compounded annual growth rate over the last five years, higher than its 11.7% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. We can take a deeper look into ResMed's earnings to better understand the drivers of its performance. As we mentioned earlier, ResMed's operating margin expanded by 4.5 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; interest expenses and taxes can also affect EPS but don't tell us as much about a company's fundamentals. In Q2, ResMed reported adjusted EPS at $2.55, up from $2.08 in the same quarter last year. This print beat analysts' estimates by 3%. Over the next 12 months, Wall Street expects ResMed's full-year EPS of $9.55 to grow 8.6%. Key Takeaways from ResMed's Q2 Results It was good to see ResMed narrowly top analysts' revenue expectations this quarter. We were also happy its constant currency revenue narrowly outperformed Wall Street's estimates. Overall, this print had some key positives. The stock remained flat at $270.94 immediately following the results. So do we think ResMed is an attractive buy at the current price? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Just one can of diet soda can increases this health risk, new study shows
Just one can of diet soda can increases this health risk, new study shows

New York Post

time2 days ago

  • New York Post

Just one can of diet soda can increases this health risk, new study shows

If you're the type of person to crack open a diet soft drink at 3 p.m. when you're looking for a pick-me-up without the calories, a new study says that this daily habit might be doing more harm than you think. New Australian research has found that knocking back just one artificially sweetened soft drink a day, like Diet Coke, Pepsi Max or Zero Sugar Solo, may increase your risk of developing type 2 diabetes by a staggering 38%. Advertisement Surprisingly, that's an even higher risk than those opting for classic full-sugar options, which were linked to a 23% rise. 4 New research found that knocking back just one artificially sweetened soft drink a day may increase your risk of developing type 2 diabetes. Pormezz – Professor Barbora de Courten, senior author on the study, told that the findings signal a need to rethink current public health strategies. 'It might be time to broaden the policy discussion not just about taxing sugar, but about reducing population-level intake of all harmful beverages, regardless of whether they're sweetened with sugar or synthetic alternatives,' said Professor de Courten, who is also a specialist physician at the Department of Diabetes & Vascular Medicine. Sugar, artificial beverages, and type 2 diabetes Advertisement 4 Professor Barbora de Courten said that the findings signal a need to rethink current public health strategies. Parilov – The longitudinal study, conducted by a team from Monash University, RMIT University and the Cancer Council Victoria, followed more than 36,000 Australian adults over nearly 14 years. 'Drinking one or more of these beverages each day – whether sweetened with sugar or artificial substitutes – was linked to a significantly higher chance of developing type 2 diabetes,' said Mr Hussen Kabthymer, who was involved in the study. Professor de Courten said the findings challenge the common belief that artificially sweetened drinks are a better option. Advertisement 4 Professor de Courten said the findings challenge the common belief that artificially sweetened drinks are a better option. – 'Artificial sweeteners often recommended to people at risk of diabetes as a healthier alternative, but our results suggest they may pose their own health risks,' she said. While the connection between sugary drinks and diabetes could mostly be explained by obesity, the connection between diet soft drinks and type 2 diabetes stayed strong even after factoring in body weight, suggesting that these drinks might directly affect how our metabolism works. 'The study, which involved participants aged 40–69 years, also adjusted for other lifestyle factors such as diet, exercise, education, and health history. What is type 2 diabetes? Advertisement 4 Type 2 diabetes is a chronic condition where the body either can't properly use insulin or doesn't produce enough of it, causing blood sugar levels to rise. Mdv Edwards – Type 2 diabetes impacts about 1.3 million Australians and over 500 million people globally, with most cases related to diet and lifestyle. It is a chronic condition where the body either can't properly use insulin or doesn't produce enough of it, causing blood sugar levels to rise. According to Diabetes Australia, it usually develops in adults over 45, but is increasingly occurring in younger age groups. Over time, uncontrolled type 2 diabetes can damage the eyes, kidneys, nerves and heart, and lead to serious complications like kidney failure, vision loss and heart disease.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store